PD-1 and PD-L1 in cancer immunotherapy: clinical implications ...
The PD-1/PD-L1 pathway plays an important role in autoimmune diseases, virus infection, transplantation immunology, and tumor immunity 1, 21 – 23. Under normal conditions, the PD-1/PD …
Immune Checkpoint Inhibitors - NCI - National Cancer Institute
Immune checkpoint inhibitors are a type of immunotherapy that block immune checkpoint proteins from binding with partner proteins. Learn about the cancers treated with checkpoint inhibitors and the side …
PD-1 and PD-L1 inhibitors - Wikipedia
The concept of blocking PD-1 and PD-L1 for the treatment of cancer was first published in 2001. [6] Pharmaceutical companies began attempting to develop drugs to block these molecules, and the first …
PD-L1 and PD-1: Immunotherapy Checkpoint Inhibitors
Mar 16, 2023 · A type of cancer immunotherapy targets PD-1 or PD-L1 with checkpoint inhibitors designed to block one or the other. Learn more about testing and results.
Immune Checkpoint Inhibitors and Their Side Effects
Immune checkpoint inhibitors, like PD-1 or PD-L1 inhibitors, are treatments that help the immune system recognize and attack cancer cells. Learn more here.
Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
An example of this is the success of the combination of PD-1/PD-L1 inhibition blockage with complementary checkpoint inhibitor CTLA-4 in melanoma and non-small cell lung cancer 3. Adoptive …
Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and ...
Oct 1, 2024 · Tumor immunotherapy has garnered considerable attention, emerging as a new standard of care in cancer treatment. The conventional targets, such as VEGF and EGFR, have been …
Understanding PD-1 and PD-L1 in Cancer Immunotherapy
Understanding the role of PD-1 and PD-L1 in cancer is essential to comprehend current immunotherapy strategies. PD-1, a checkpoint protein on T-cells, and PD-L1, its ligand found on tumor cells, have …
Use of PD-1 vs PD-L1 Inhibitors in Patients With Cancer
Dec 26, 2019 · This systematic review and meta-analysis of randomized clinical trials examines use of programmed cell death 1 (PD-1) vs programmed cell death–ligand 1 (PD-L1) treatment in patients …
FDA Approves First Ovarian Cancer Immunotherapy for PD-L1 ...
Feb 15, 2026 · For many years, immunotherapy trials in ovarian cancer did not improve survival. This study represents an important milestone by identifying a group of patients—those with PD …